Role of Inflammation and Oxidative Stress Mediators in Gliomas
Abstract
:1. Introduction
2. Cytokines Escape from the Immune Response in Gliomas
3. The Link between Inflammation and Cancer: The Nuclear Factor-κB
4. Nitric Oxide and Its Controversial Role in Gliomagenesis
5. Cyclooxygenase in Glioma Biology
6. Molecular Epidemiology to Identify Inflammation-Related Risk Factors
7. MicroRNAs as Emerging Regulatory Molecules in Inflammation and Cancer
8. Conclusions
References
- Ashby, L.S.; Ryken, T.C. Management of malignant glioma: steady progress with multimodal approaches. Neurosurg. Focus 2006, 20, E3. [Google Scholar] [CrossRef]
- Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70. [Google Scholar]
- Philip, M.; Rowley, D.A.; Schreiber, H. Inflammation as a tumor promoter in cancer induction. Semin. Cancer Biol. 2004, 14, 433–439. [Google Scholar] [CrossRef]
- Alavanja, M.C.; Brownson, R.C.; Boice, J.D., Jr.; Hock, E. Preexisting lung disease and lung cancer among nonsmoking women. Am. J. Epidemiol. 1992, 136, 623–632. [Google Scholar]
- Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature 2002, 420, 860–867. [Google Scholar] [CrossRef]
- Macarthur, M.; Hold, G.L.; El-Omar, E.M. Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286, G515–520. [Google Scholar] [CrossRef]
- Block, T.M.; Mehta, A.S.; Fimmel, C.J.; Jordan, R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003, 22, 5093–5107. [Google Scholar] [CrossRef]
- Minelli, A.; Bellezza, I.; Conte, C.; Culig, Z. Oxidative stress-related aging: A role for prostate cancer? Biochim. Biophys. Acta 2009, 1795, 83–91. [Google Scholar]
- Rossi, M.L.; Cruz-Sanchez, F.; Hughes, J.T.; Esiri, M.M.; Coakham, H.B.; Moss, T.H. Mononuclear cell infiltrate and HLA-DR expression in low grade astrocytomas. An immunohistological study of 23 cases. Acta Neuropathol. 1988, 76, 281–286. [Google Scholar] [CrossRef]
- Rossi, M.L.; Hughes, J.T.; Esiri, M.M.; Coakham, H.B.; Brownell, D.B. Immunohistological study of mononuclear cell infiltrate in malignant gliomas. Acta Neuropathol. 1987, 74, 269–277. [Google Scholar] [CrossRef]
- Morimura, T.; Neuchrist, C.; Kitz, K.; Budka, H.; Scheiner, O.; Kraft, D.; Lassmann, H. Monocyte subpopulations in human gliomas: expression of Fc and complement receptors and correlation with tumor proliferation. Acta Neuropathol. 1990, 80, 287–294. [Google Scholar] [CrossRef]
- Roggendorf, W.; Strupp, S.; Paulus, W. Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol. 1996, 92, 288–293. [Google Scholar] [CrossRef]
- Graeber, M.B.; Bise, K.; Mehraein, P. CR3/43, a marker for activated human microglia: application to diagnostic neuropathology. Neuropathol. Appl. Neurobiol. 1994, 20, 406–408. [Google Scholar] [CrossRef]
- Flugel, A.; Labeur, M.S.; Grasbon-Frodl, E.M.; Kreutzberg, G.W.; Graeber, M.B. Microglia only weakly present glioma antigen to cytotoxic T cells. Int. J. Dev. Neurosci. 1999, 17, 547–556. [Google Scholar] [CrossRef]
- Constam, D.B.; Philipp, J.; Malipiero, U.V.; ten Dijke, P.; Schachner, M.; Fontana, A. Differential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J. Immunol. 1992, 148, 1404–1410. [Google Scholar]
- Platten, M.; Wick, W.; Weller, M. Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape. Microsc. Res. Tech. 2001, 52, 401–410. [Google Scholar] [CrossRef]
- Wojtowicz-Praga, S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J. Immunother. 1997, 20, 165–177. [Google Scholar] [CrossRef]
- Huettner, C.; Czub, S.; Kerkau, S.; Roggendorf, W.; Tonn, J.C. Interleukin 10 is expressed in human gliomas in vivo and increases glioma cell proliferation and motility in vitro. Anticancer Res. 1997, 17, 3217–3224. [Google Scholar]
- Hishii, M.; Nitta, T.; Ishida, H.; Ebato, M.; Kurosu, A.; Yagita, H.; Sato, K.; Okumura, K. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 1995, 37, 1160-1166; discussion 1166–1167. [Google Scholar]
- Conti, A.; Cardali, S.; Genovese, T.; Di Paola, R.; La Rosa, G. Role of inflammation in the secondary injury following experimental spinal cord trauma. J. Neurosurg. Sci. 2003, 47, 89–94. [Google Scholar]
- Conti, A.; Miscusi, M.; Cardali, S.; Germano, A.; Suzuki, H.; Cuzzocrea, S.; Tomasello, F. Nitric oxide in the injured spinal cord: synthases cross-talk, oxidative stress and inflammation. Brain. Res. Rev. 2007, 54, 205–218. [Google Scholar] [CrossRef]
- Messina, S.; Altavilla, D.; Aguennouz, M.; Seminara, P.; Minutoli, L.; Monici, M.C.; Bitto, A.; Mazzeo, A.; Marini, H.; Squadrito, F.; Vita, G. Lipid peroxidation inhibition blunts nuclear factor-kappaB activation, reduces skeletal muscle degeneration, and enhances muscle function in mdx mice. Am. J. Pathol. 2006, 168, 918–926. [Google Scholar] [CrossRef]
- Monici, M.C.; Aguennouz, M.; Mazzeo, A.; Messina, C.; Vita, G. Activation of nuclear factor-kappaB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology 2003, 60, 993–997. [Google Scholar] [CrossRef]
- Gilmore, T.D. The Re1/NF-kappa B/I kappa B signal transduction pathway and cancer. Cancer Treat. Res. 2003, 115, 241–265. [Google Scholar] [CrossRef]
- Karin, M. NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harbor Perspect. Biol. 2009, 1, a000141. [Google Scholar] [CrossRef]
- Nagai, S.; Washiyama, K.; Kurimoto, M.; Takaku, A.; Endo, S.; Kumanishi, T. Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J. Neurosurg. 2002, 96, 909–917. [Google Scholar] [CrossRef]
- Gill, J.S.; Zhu, X.; Moore, M.J.; Lu, L.; Yaszemski, M.J.; Windebank, A.J. Effects of NFkappaB decoy oligonucleotides released from biodegradable polymer microparticles on a glioblastoma cell line. Biomaterials 2002, 23, 2773–2781. [Google Scholar] [CrossRef]
- Weaver, K.D.; Yeyeodu, S.; Cusack, J.C., Jr.; Baldwin, A.S., Jr.; Ewend, M.G. Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J. Neurooncol. 2003, 61, 187–196. [Google Scholar] [CrossRef]
- Conti, A.; Ageunnouz, M.; La Torre, D.; Cardali, S.; Angileri, F.F.; Buemi, C.; Tomasello, C.; Iacopino, D.G.; D'Avella, D.; Vita, G.; Tomasello, F. Expression of the tumor necrosis factor receptor-associated factors 1 and 2 and regulation of the nuclear factor-kappaB antiapoptotic activity in human gliomas. J. Neurosurg. 2005, 103, 873–881. [Google Scholar] [CrossRef]
- Beg, A.A.; Baltimore, D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science 1996, 274, 782–784. [Google Scholar] [CrossRef]
- Liu, Z.G.; Hsu, H.; Goeddel, D.V.; Karin, M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 1996, 87, 565–576. [Google Scholar] [CrossRef]
- Van Antwerp, D.J.; Martin, S.J.; Kafri, T.; Green, D.R.; Verma, I.M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996, 274, 787–789. [Google Scholar] [CrossRef]
- Wang, C.Y.; Mayo, M.W.; Korneluk, R.G.; Goeddel, D.V.; Baldwin, A.S., Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998, 281, 1680–1683. [Google Scholar] [CrossRef]
- Cheng, G.; Baltimore, D. TANK, a co-inducer with TRAF2 of TNF- and CD 40L-mediated NF-kappaB activation. Genes Dev. 1996, 10, 963–973. [Google Scholar] [CrossRef]
- Rothe, M.; Sarma, V.; Dixit, V.M.; Goeddel, D.V. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science 1995, 269, 1424–1427. [Google Scholar] [CrossRef]
- Angileri, F.F.; Aguennouz, M.; Conti, A.; La Torre, D.; Cardali, S.; Crupi, R.; Tomasello, C.; Germano, A.; Vita, G.; Tomasello, F. Nuclear factor-kappaB activation and differential expression of survivin and Bcl-2 in human grade 2-4 astrocytomas. Cancer 2008, 112, 2258–2266. [Google Scholar]
- Wang, H.; Lathia, J.D.; Wu, Q.; Wang, J.; Li, Z.; Heddleston, J.M.; Eyler, C.E.; Elderbroom, J.; Gallagher, J.; Schuschu, J.; MacSwords, J.; Cao, Y.; McLendon, R.E.; Wang, X.F.; Hjelmeland, A.B.; Rich, J.N. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells 2009, 27, 2393–2404. [Google Scholar] [CrossRef]
- Brat, D.J.; Bellail, A.C.; Van Meir, E.G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 2005, 7, 122–133. [Google Scholar] [CrossRef]
- Li, A.; Dubey, S.; Varney, M.L.; Dave, B.J.; Singh, R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J. Immunol. 2003, 170, 3369–3376. [Google Scholar]
- Shono, T.; Ono, M.; Izumi, H.; Jimi, S.I.; Matsushima, K.; Okamoto, T.; Kohno, K.; Kuwano, M. Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol. Cell Biol. 1996, 16, 4231–4239. [Google Scholar]
- Hussain, S.P.; Hofseth, L.J.; Harris, C.C. Radical causes of cancer. Nat. Rev. Cancer 2003, 3, 276–285. [Google Scholar] [CrossRef]
- La Rosa, G.; Cardali, S.; Genovese, T.; Conti, A.; Di Paola, R.; La Torre, D.; Cacciola, F.; Cuzzocrea, S. Inhibition of the nuclear factor-kappaB activation with pyrrolidine dithiocarbamate attenuating inflammation and oxidative stress after experimental spinal cord trauma in rats. J. Neurosurg. Spine 2004, 1, 311–321. [Google Scholar] [CrossRef]
- Genovese, T.; Mazzon, E.; Mariotto, S.; Menegazzi, M.; Cardali, S.; Conti, A.; Suzuki, H.; Bramanti, P.; Cuzzocrea, S. Modulation of nitric oxide homeostasis in a mouse model of spinal cord injury. J. Neurosurg. Spine 2006, 4, 145–153. [Google Scholar] [CrossRef]
- Pryor, W.A.; Squadrito, G.L. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am. J. Physiol. 1995, 268, L699–722. [Google Scholar]
- Crow, J.P.; Beckman, J.S. Reactions between nitric oxide, superoxide, and peroxynitrite: footprints of peroxynitrite in vivo. Adv. Pharmacol. 1995, 34, 17–43. [Google Scholar] [CrossRef]
- Ghosh, A.; Mukherjee, J.; Bhattacharjee, M.; Sarkar, P.; Acharya, S.; Chaudhuri, S. The other side of the coin: beneficiary effect of 'oxidative burst' upsurge with T11TS facilitates the elimination of glioma cells. Cell Mol. Biol. (Noisy-le-grand) 2007, 53, 53–62. [Google Scholar]
- Hofseth, L.J. Nitric oxide as a target of complementary and alternative medicines to prevent and treat inflammation and cancer. Cancer Lett. 2008, 268, 10–30. [Google Scholar] [CrossRef]
- Visconti, R.; Grieco, D. New insights on oxidative stress in cancer. Curr. Opin. Drug Discov. Devel. 2009, 12, 240–245. [Google Scholar]
- Towner, R.A.; Smith, N.; Doblas, S.; Garteiser, P.; Watanabe, Y.; He, T.; Saunders, D.; Herlea, O.; Silasi-Mansat, R.; Lupu, F. In vivo detection of inducible nitric oxide synthase in rodent gliomas. Free Radic. Biol. Med. 2009.
- Cobbs, C.S.; Brenman, J.E.; Aldape, K.D.; Bredt, D.S.; Israel, M.A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 1995, 55, 727–730. [Google Scholar]
- Bakshi, A.; Nag, T.C.; Wadhwa, S.; Mahapatra, A.K.; Sarkar, C. The expression of nitric oxide synthases in human brain tumours and peritumoral areas. J. Neurol. Sci. 1998, 155, 196–203. [Google Scholar] [CrossRef]
- Garbossa, D.; Fontanella, M.; Pagni, C.A.; Vercelli, A. Nitric oxide synthase and cytochrome c oxidase changes in the tumoural and peritumoural cerebral cortex. Acta Neurochir. (Wien) 2001, 143, 897–908. [Google Scholar] [CrossRef]
- Broholm, H.; Rubin, I.; Kruse, A.; Braendstrup, O.; Schmidt, K.; Skriver, E.B.; Lauritzen, M. Nitric oxide synthase expression and enzymatic activity in human brain tumors. Clin. Neuropathol. 2003, 22, 273–281. [Google Scholar]
- Cobbs, C.S.; Whisenhunt, T.R.; Wesemann, D.R.; Harkins, L.E.; Van Meir, E.G.; Samanta, M. Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res. 2003, 63, 8670–8673. [Google Scholar]
- van der Vliet, A.; Hristova, M.; Cross, C.E.; Eiserich, J.P.; Goldkorn, T. Peroxynitrite induces covalent dimerization of epidermal growth factor receptors in A431 epidermoid carcinoma cells. J. Biol. Chem. 1998, 273, 31860–31866. [Google Scholar]
- Li, X.; De Sarno, P.; Song, L.; Beckman, J.S.; Jope, R.S. Peroxynitrite modulates tyrosine phosphorylation and phosphoinositide signalling in human neuroblastoma SH-SY5Y cells: attenuated effects in human 1321N1 astrocytoma cells. Biochem. J. 1998, 331 (Pt 2), 599–606. [Google Scholar]
- Zhang, P.; Wang, Y.Z.; Kagan, E.; Bonner, J.C. Peroxynitrite targets the epidermal growth factor receptor, Raf-1, and MEK independently to activate MAPK. J. Biol. Chem. 2000, 275, 22479–22486. [Google Scholar] [CrossRef]
- Kundu, J.K.; Surh, Y.J. Inflammation: gearing the journey to cancer. Mutat. Res. 2008, 659, 15–30. [Google Scholar] [CrossRef]
- Thiele, G.M.; Duryee, M.J.; Willis, M.S.; Sorrell, M.F.; Freeman, T.L.; Tuma, D.J.; Klassen, L.W. Malondialdehyde-acetaldehyde (MAA) modified proteins induce pro-inflammatory and pro-fibrotic responses by liver endothelial cells. Comp. Hepatol. 2004, 3 (Suppl. 1), S25. [Google Scholar]
- Ying, L.; Hofseth, A.B.; Browning, D.D.; Nagarkatti, M.; Nagarkatti, P.S.; Hofseth, L.J. Nitric oxide inactivates the retinoblastoma pathway in chronic inflammation. Cancer Res. 2007, 67, 9286–9293. [Google Scholar]
- Suh, Y.A.; Arnold, R.S.; Lassegue, B.; Shi, J.; Xu, X.; Sorescu, D.; Chung, A.B.; Griendling, K.K.; Lambeth, J.D. Cell transformation by the superoxide-generating oxidase Mox1. Nature 1999, 401, 79–82. [Google Scholar] [CrossRef]
- Lu, H.; Ouyang, W.; Huang, C. Inflammation, a key event in cancer development. Mol. Cancer Res. 2006, 4, 221–233. [Google Scholar] [CrossRef]
- Chandrasekharan, N.V.; Dai, H.; Roos, K.L.; Evanson, N.K.; Tomsik, J.; Elton, T.S.; Simmons, D.L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc. Natl. Acad. Sci. USA 2002, 99, 13926–13931. [Google Scholar]
- Smith, W.L.; Garavito, R.M.; DeWitt, D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J. Biol. Chem. 1996, 271, 33157–33160. [Google Scholar]
- Harris, R.E. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009, 17, 55–67. [Google Scholar] [CrossRef]
- Shono, T.; Tofilon, P.J.; Bruner, J.M.; Owolabi, O.; Lang, F.F. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001, 61, 4375–4381. [Google Scholar]
- Deininger, M.H.; Weller, M.; Streffer, J.; Mittelbronn, M.; Meyermann, R. Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo. Acta Neuropathol. 1999, 98, 240–244. [Google Scholar] [CrossRef]
- Joki, T.; Heese, O.; Nikas, D.C.; Bello, L.; Zhang, J.; Kraeft, S.K.; Seyfried, N.T.; Abe, T.; Chen, L.B.; Carroll, R.S.; Black, P.M. Expression of cyclooxygenase 2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 2000, 60, 4926–4931. [Google Scholar]
- Tsujii, M.; Kawano, S.; Tsuji, S.; Sawaoka, H.; Hori, M.; DuBois, R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93, 705–716. [Google Scholar] [CrossRef]
- Kang, K.B.; Wang, T.T.; Woon, C.T.; Cheah, E.S.; Moore, X.L.; Zhu, C.; Wong, M.C. Enhancement of glioblastoma radioresponse by a selective COX-2 inhibitor celecoxib: inhibition of tumor angiogenesis with extensive tumor necrosis. Int. J. Radiat. Oncol. Biol. Phys. 2007, 67, 888–896. [Google Scholar] [CrossRef]
- Bijnsdorp, I.V.; van den Berg, J.; Kuipers, G.K.; Wedekind, L.E.; Slotman, B.J.; van Rijn, J.; Lafleur, M.V.; Sminia, P. Radiosensitizing potential of the selective cyclooygenase-2 (COX-2) inhibitor meloxicam on human glioma cells. J. Neurooncol. 2007, 85, 25–31. [Google Scholar] [CrossRef]
- Masferrer, J.L.; Leahy, K.M.; Koki, A.T.; Zweifel, B.S.; Settle, S.L.; Woerner, B.M.; Edwards, D.A.; Flickinger, A.G.; Moore, R.J.; Seibert, K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000, 60, 1306–1311. [Google Scholar]
- Wagemakers, M.; van der Wal, G.E.; Cuberes, R.; Alvarez, I.; Andres, E.M.; Buxens, J.; Vela, J.M.; Moorlag, H.; Mooij, J.J.; Molema, G. COX-2 Inhibition Combined with Radiation Reduces Orthotopic Glioma Outgrowth by Targeting the Tumor Vasculature. Transl. Oncol. 2009, 2, 1–7. [Google Scholar] [CrossRef]
- Annabi, B.; Laflamme, C.; Sina, A.; Lachambre, M.P.; Beliveau, R. A MT1-MMP/NF-kappaB signaling axis as a checkpoint controller of COX-2 expression in CD133+ U87 glioblastoma cells. J. Neuroinflammation 2009, 6, 8. [Google Scholar] [CrossRef]
- Liu, G.; Yuan, X.; Zeng, Z.; Tunici, P.; Ng, H.; Abdulkadir, I.R.; Lu, L.; Irvin, D.; Black, K.L.; Yu, J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5, 67. [Google Scholar] [CrossRef]
- Gu, J.; Liu, Y.; Kyritsis, A.P.; Bondy, M.L. Molecular epidemiology of primary brain tumors. Neurotherapeutics 2009, 6, 427–435. [Google Scholar] [CrossRef]
- Brenner, A.V.; Butler, M.A.; Wang, S.S.; Ruder, A.M.; Rothman, N.; Schulte, P.A.; Chanock, S.J.; Fine, H.A.; Linet, M.S.; Inskip, P.D. Single-nucleotide polymorphisms in selected cytokine genes and risk of adult glioma. Carcinogenesis 2007, 28, 2543–2547. [Google Scholar]
- Wiemels, J.L.; Wilson, D.; Patil, C.; Patoka, J.; McCoy, L.; Rice, T.; Schwartzbaum, J.; Heimberger, A.; Sampson, J.H.; Chang, S.; Prados, M.; Wiencke, J.K.; Wrensch, M. IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. Int. J. Cancer 2009, 125, 680–687. [Google Scholar]
- Schwartzbaum, J.A.; Fisher, J.L.; Aldape, K.D.; Wrensch, M. Epidemiology and molecular pathology of glioma. Nat. Clin. Pract. Neurol. 2006, 2, 494–503; quiz 491 p following 516. [Google Scholar]
- Schwartzbaum, J.; Jonsson, F.; Ahlbom, A.; Preston-Martin, S.; Malmer, B.; Lonn, S.; Soderberg, K.; Feychting, M. Prior hospitalization for epilepsy, diabetes, and stroke and subsequent glioma and meningioma risk. Cancer Epidemiol. Biomarkers Prev. 2005, 14, 643–650. [Google Scholar] [CrossRef]
- Linos, E.; Raine, T.; Alonso, A.; Michaud, D. Atopy and risk of brain tumors: a meta-analysis. J. Natl. Cancer Inst. 2007, 99, 1544–1550. [Google Scholar] [CrossRef]
- de Moor, C.H.; Meijer, H.; Lissenden, S. Mechanisms of translational control by the 3' UTR in development and differentiation. Semin. Cell Dev. Biol. 2005, 16, 49–58. [Google Scholar] [CrossRef]
- Lai, E.C. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat. Genet. 2002, 30, 363–364. [Google Scholar] [CrossRef]
- Robins, H.; Press, W.H. Human microRNAs target a functionally distinct population of genes with AT-rich 3' UTRs. Proc. Natl. Acad. Sci. USA 2005, 102, 15557–15562. [Google Scholar] [CrossRef]
- Stark, A.; Brennecke, J.; Bushati, N.; Russell, R.B.; Cohen, S.M. Animal MicroRNAs confer robustness to gene expression and have a significant impact on 3'UTR evolution. Cell 2005, 123, 1133–1146. [Google Scholar] [CrossRef]
- Sun, M.; Hurst, L.D.; Carmichael, G.G.; Chen, J. Evidence for a preferential targeting of 3'-UTRs by cis-encoded natural antisense transcripts. Nucleic Acids Res. 2005, 33, 5533–5543. [Google Scholar] [CrossRef]
- Meltzer, P.S. Cancer genomics: small RNAs with big impacts. Nature 2005, 435, 745–746. [Google Scholar] [CrossRef]
- Calin, G.A.; Croce, C.M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 2006, 6, 857–866. [Google Scholar] [CrossRef]
- Cimmino, A.; Calin, G.A.; Fabbri, M.; Iorio, M.V.; Ferracin, M.; Shimizu, M.; Wojcik, S.E.; Aqeilan, R.I.; Zupo, S.; Dono, M.; Rassenti, L.; Alder, H.; Volinia, S.; Liu, C.G.; Kipps, T.J.; Negrini, M.; Croce, C.M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 2005, 102, 13944–13949. [Google Scholar] [CrossRef]
- Nicoloso, M.S.; Calin, G.A. MicroRNA involvement in brain tumors: from bench to bedside. Brain Pathol. 2008, 18, 122–129. [Google Scholar] [CrossRef]
- Conti, A.; Aguennouz, M.; La Torre, D.; Tomasello, C.; Cardali, S.; Angileri, F.F.; Maio, F.; Cama, A.; Germano, A.; Vita, G.; Tomasello, F. miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. J. Neurooncol. 2009, 93, 325–332. [Google Scholar] [CrossRef]
- Wu, F.; Zikusoka, M.; Trindade, A.; Dassopoulos, T.; Harris, M.L.; Bayless, T.M.; Brant, S.R.; Chakravarti, S.; Kwon, J.H. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 2008, 135, 1624–1635.e24. [Google Scholar] [CrossRef]
- Krichevsky, A.M.; Gabriely, G. miR-21: a small multi-faceted RNA. J. Cell Mol. Med. 2009, 13, 39–53. [Google Scholar] [CrossRef]
- Frankel, L.B.; Christoffersen, N.R.; Jacobsen, A.; Lindow, M.; Krogh, A.; Lund, A.H. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J. Biol. Chem. 2008, 283, 1026–1033. [Google Scholar]
- Zhu, S.; Si, M.L.; Wu, H.; Mo, Y.Y. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J. Biol. Chem. 2007, 282, 14328–14336. [Google Scholar]
- Meng, F.; Henson, R.; Wehbe-Janek, H.; Ghoshal, K.; Jacob, S.T.; Patel, T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007, 133, 647–658. [Google Scholar] [CrossRef]
- Liu, M.; Wu, H.; Liu, T.; Li, Y.; Wang, F.; Wan, H.; Li, X.; Tang, H. Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res. 2009, 19, 828–837. [Google Scholar] [CrossRef]
- Si, M.L.; Zhu, S.; Wu, H.; Lu, Z.; Wu, F.; Mo, Y.Y. miR-21-mediated tumor growth. Oncogene 2007, 26, 2799–2803. [Google Scholar] [CrossRef]
- Loffler, D.; Brocke-Heidrich, K.; Pfeifer, G.; Stocsits, C.; Hackermuller, J.; Kretzschmar, A.K.; Burger, R.; Gramatzki, M.; Blumert, C.; Bauer, K.; Cvijic, H.; Ullmann, A.K.; Stadler, P.F.; Horn, F. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 2007, 110, 1330–1333. [Google Scholar] [CrossRef]
- Seike, M.; Goto, A.; Okano, T.; Bowman, E.D.; Schetter, A.J.; Horikawa, I.; Mathe, E.A.; Jen, J.; Yang, P.; Sugimura, H.; Gemma, A.; Kudoh, S.; Croce, C.M.; Harris, C.C. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc. Natl. Acad. Sci. USA 2009, 106, 12085–12090. [Google Scholar] [CrossRef]
- Lu, T.X.; Munitz, A.; Rothenberg, M.E. MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J. Immunol. 2009, 182, 4994–5002. [Google Scholar] [CrossRef]
© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Conti, A.; Gulì, C.; La Torre, D.; Tomasello, C.; Angileri, F.F.; Aguennouz, M. Role of Inflammation and Oxidative Stress Mediators in Gliomas. Cancers 2010, 2, 693-712. https://doi.org/10.3390/cancers2020693
Conti A, Gulì C, La Torre D, Tomasello C, Angileri FF, Aguennouz M. Role of Inflammation and Oxidative Stress Mediators in Gliomas. Cancers. 2010; 2(2):693-712. https://doi.org/10.3390/cancers2020693
Chicago/Turabian StyleConti, Alfredo, Carlo Gulì, Domenico La Torre, Chiara Tomasello, Filippo F. Angileri, and M’Hammed Aguennouz. 2010. "Role of Inflammation and Oxidative Stress Mediators in Gliomas" Cancers 2, no. 2: 693-712. https://doi.org/10.3390/cancers2020693